BRAF Protein as a Novel Driver and Therapeutic Target for Chronic Nerve Pain

Researchers at The University of Texas MD Anderson Cancer Center published a study on August 30, 2026, in Science Signaling revealing that the cancer-linked protein BRAF plays a critical role in driving chronic neuropathic pain following nerve injury. Co-led by Dr. Shao-Rui Chen and Dr. Hui-Lin Pan, the team discovered that BRAF travels from peripheral sensory nerves to spinal synapses, where it activates molecular signaling that excessively strengthens NMDA receptor activity and sustains pain signaling. The research team demonstrated that administering existing cancer drugs, specifically the BRAF inhibitor vemurafenib and the MEK inhibitor selumetinib, effectively reduced touch, pressure, and heat pain sensitivity in preclinical models without altering normal responses in uninjured subjects. Furthermore, genetic experiments confirmed that deleting the Braf gene reduced persistent pain sensitivity, whereas directly activating BRAF induced pain sensitivity in uninjured models. This breakthrough establishes a direct mechanistic bridge between cancer signaling pathways and pathological pain processing in the central nervous system. By identifying how BRAF recruitment to spinal sensory synapses potentiates transsynaptic NMDA receptor activity, the study uncovers a novel therapeutic target that can potentially bypass traditional opioid treatments. The clinical implication of this research offers a promising pathway for rapidly repurposing FDA-approved oncology drugs to treat severe chronic nerve pain. Before human clinical trials can commence, researchers must establish precise dosing guidelines, optimize delivery methods, and fully evaluate potential side effects, opening a new frontier in non-opioid pain management.